Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031)2026
Description
Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Overview:
The Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).
This report delivers a comprehensive overview of the Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:
Major Highlights
This report delivers a comprehensive overview of the Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
The Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).
This report delivers a comprehensive overview of the Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:
Major Highlights
This report delivers a comprehensive overview of the Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Tuberculosis – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.
Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
Table of Contents
223 Pages
- TUBERCULOSIS PIPELINE ANALYSIS
- • Tuberculosis is considered a chronic infectious disease caused by a bacterium called Mycobacterium tuberculosis and is a highly contagious disease
- • . This bacterium is present in the air and is communicable. It occurs by inhaling tuberculosis bacilli in the air. It usually affects the lungs (pulmonary tuberculosis) and can also target other body parts, including the spine, brain, and kidney.
- • The bacterial infection spreads through lymph nodes, bloodstream to any organ in the body. Mainly tuberculosis is of two types including latent tuberculosis and active tuberculosis. In latent TB condition, the person infected with the bacteria but it is in an active state and causes no symptoms.
- • It isn’t contagious and also called inactive tuberculosis (or) TB but can turn into active TB. Thus treatment is important for latent TB and for controlling the spread of TB.
- • Active Tuberculosis stage enables bacteria spread to others. It may occur in initial stages of infection with the Mycobacterium tuberculosis bacteria, or it might occur years later.
- • The development pipeline was remained thin, but for the first time in decades, multiple drugs are found in the clinical development of tuberculosis. Some discovery efforts are directed towards designing drugs that retain potent anti-TB activity but showing fewer undesirable attributes including water-soluble analogs of clofaziminethat are less likely to cause skin discoloration or oxazolidinones showing less mitochondrial toxicity and reduced risk of dose-limiting neuropathy compared with linezolid. Several new chemical entities have progressed to clinical evaluation, including nitroimidazoles (delamanid, PA-824, and TBA-354), oxazolidinones (sutezolid and AZD5847), the ATP synthase inhibitor, bedaquiline and an ethambutol analog, SQ109. Bedaquiline was registered with the Food and Drug Administration after expedited review and is available for treatment of multi-drug-resistant tuberculosis (MDR-TB) in some settings.
- • Efforts to optimize rifamycin antibiotics (rifampin and rifapentine) or repurpose drugs showing good anti-TB activity (moxifloxacin) are under study, and these drugs are considered as a part of the tuberculosis drug pipeline.
- • TB Alliance in conjunction with Janssen Pharmaceuticals is conducting Nix-TB trial that involves a combination of drugs, pretomanid, linezolid, and bedaquiline, which is definitely used as a cure for Extensively Drug Resistant (XDR) form of the disease.
- • Dishman Group has received a license agreement from Janssen Pharmaceutica, (a subsidiary of J&J) to produce the active pharmaceutical ingredient (API) for the drug Sirturo (bedaquiline).
- • The drugs that are under phase III clinical trial development include Bedaquiline, FS-1, Delamanid, Isoniazid, Rifapentine, Moxifloxacin, Rifampin, Linezolid, Tenofovir, Lamivudine, and others, which are going to add the growth for the tuberculosis global market.
- • The driving factors of the TB market include a rise in the number of tuberculosis patients, increasing awareness among people, and the increasing number of research and development activities in developing novel drugs.
- • Moreover, technological advancement in early stage detection, and government & non-government organizations initiating the promotion of tuberculosis drugs are further leading to TB market growth. Anyway, some of the adverse drug reactions to the people may inhibit the tuberculosis market growth.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
